Alert First !!!
Nepal has reported its first ever case of Monkeypox infection on 20 Dec 2024 who was a migrant worker returned from Saudi Arabia on the previous day. This event has ignited an alert in the medical system as well as public domain in order to remain untouched from the disease of public health concern. Kindly read further in order to get more details ...
Brief History Of Monkypox Outbreak
Unfortunately on recent outbreak started from UK, world has miserably failed to contain the spread of virus and it is taking its toll globally and spreading further. First cases of west African strain was identified on 6 May 2022, followed by six more such events within a week. As per High Consequences Infectious Disease (HCID) network, total of 1735 cases were already reported by mid July, most of which are centered around London. Virus has made its way throughout the Europe, America and our close neighbor India as well.
Clinical Progression of Monkeypox Infection
- For initial 10 - 12 days, there is an incubation period
- Prodromal symptoms of headache, fever, malaise, weakness etc.
- Lymphadenopathy: Localized or general swelling of lymph nodes is the distinguishing clinical presentation of monkeypox from other infections
- Rashes develop very soon which further progress to well formed lesion. Initial macular rashes develops to papules, vesicles and pustules. Monekypox lesion are well circumscribed, deep and umblicated (a dot like pattern is noted on the top).
- Lesions generally confined to facial, anorectal and genital regions,
- Generally 2 - 4 weeks of infection, the pustules get crusted and scabbed over and the illness resolves.
Treatment and Prevention
- Medicines: As per the Food and Drug Administration (FDA), there are no approved treatment specific for monkeypox virus. However, treatment of smallpox and cytomegalovirus also works for Monekypox as well. A drug candidate named "Tecovirimat" has shown some promising results from animal studies but scant is known about it's effectiveness in human; further clinical trials are under the way. Other potential treatment candidates include VIGIV, cidofovir, Brincidofovir, for which also extensive effectiveness data is yet to come.
- Vaccination: Pre-exposure prophylaxis in the form of vaccination is the currently available most effective way of disease prevention. For various reasons, Center for Disease Control and Prevention (CDC) has suggested only high risk personnel such as laboratory workers be get vaccinated against Orthopoxviruses which is effective against Smallpox as well as Monkeypox. Routine immunization for all health workers is not a current recommendation. The two FDA licensed vaccine candidates are JYNNEOS and ACAM2000. The former is to be taken in two dosage 28 days apart and later one in single dose.
- Public Health Measures: Active surveillance, investigation and contact tracing is mandatory to prevent human to human transmission by rapidly identifying, isolation and treatment of infected individuals and halt the speed of new transmission. Along with these measures since transmission of monkeypox is somewhat similar to COVID-19 (not in intensity), common public health measures are also similar. Routine healthy practice includes avoiding unnecessary public gathering, wearing mask in public places, washing hands frequently, avoiding unhealthy sexual behaviors and avoiding pregnancy by suspected women.
Is There A Chance of Monkeypox Pandemic ?
Considering all the reported information about the natural history of disease, Monkeypox can affect human life significantly by becoming a major public health concern for a particular point of time at its worst but resulting into pandemic is far beyond from its ability. There are many attributable factors needed to create pandemic such as rate of disease spread, mode of disease transmission, incubation period of disease, clinical severity, effectiveness of available treatment options and preparedness of health facility in different countries. Monkeypox stands with feeble strength in all these aspects. Firstly, transmission potential of Monkeypox is far more slower and weaker than any other pandemic we have witnessed (like smallpox, COVID-19 etc); in order to transmit disease, relatively longer close physical contact is needed which itself limits rapid spread of disease. Also clinical severity of the disease is very less since there is no systemic involvement of the virus, which makes death due to Monkeypox virus alone extremely unlikely. Also, if we suffice the availability of smallpox vaccine before the disease take over and make use of all the strengthened (and already sensitized) healthcare system and augment it little further, existing healthcare facility can easily withstand burden of this disease.
Monkeypox will be a big burden only if respected health authority of the countries fail to implement common public health guideline suggested by experts.
Thank You !!!
References:
1. https://www.nepalitimes.com/banner/big-story-of-small-pox-in-nepal/
2. https://www.cdc.gov/poxvirus/monkeypox/clinicians/clinical-recognition.html#:~:text=Persons%20with%20monkeypox%20will%20develop,lymphadenopathy%20(swollen%20lymph%20nodes).
3. https://www.bbc.com/news/world-asia-india-62344928
4. https://www.bmj.com/content/378/bmj-2022-072410
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157091/#:~:text=Between%20September%202017%20and%2031,region%20of%20Nigeria%20%5B16%5D.
6. India reports Asia's first monkeypox-related death; exact cause unconfirmed | The Times of Israel
7. https://www.who.int/southeastasia/news/detail/24-07-2022-enhance-surveillance--public-health-measures-for-monkeypox--who
Very informative Dr Suman
ReplyDelete